Why the study?
In REPRIEVE, pitavastatin reduced MACE in people with HIV, motivating an investigation into its effects on noncalcified coronary plaque and inflammatory biomarkers as potential mechanisms.
Does pitavastatin reduce noncalcified coronary plaque volume and progression in people with HIV at low to moderate CVD risk?
Does pitavastatin reduce noncalcified coronary plaque volume and progression in people with HIV at low to moderate CVD risk?
In people with HIV at low to moderate CVD risk, pitavastatin reduced noncalcified coronary plaque volume and progression, providing a mechanistic explanation for the cardiovascular benefits observed in the REPRIEVE trial.
No takes yet. Share an insight, caveat, or question.
Supports pitavastatin in HIV primary prevention; extends REPRIEVE by identifying noncalcified plaque reduction as mechanism.
Lu et al. (2024) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: